<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563781</url>
  </required_header>
  <id_info>
    <org_study_id>CICOG-2-3-18/12</org_study_id>
    <nct_id>NCT03563781</nct_id>
  </id_info>
  <brief_title>SEntine Lymph Node in earLY Ovarian Cancer (SELLY)</brief_title>
  <acronym>SELLY</acronym>
  <official_title>SEntine Lymph Node in earLY Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims at investigating the feasibility, the detection rate and the negative
      predictive value of sentinel node in predicting the presence or absence of lymph node
      metastasis in ovarian cancer patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with early stage ovarian cancer have a good prognosis. However, nearly 15% of the
      initially diagnosed as early stage ovarian cancers, will be upstaged after an appropriate
      surgical staging due to lymphatic metastasis, despite of preoperative radiological data.
      Therefore, complete pelvic and para-aortic lymphadenectomy in these patients represents a
      crucial procedure. On the other hand, nodal dissection may be associated with threatening
      intra- and post-operative complications.

      If feasible and accurate, the sentinel lymph node procedure could be a modality to avoid
      unnecessary radical lymphadenectomy without missing important information on nodal status.

      With the present study we aim at exploring the role of sentinel node dissection in early
      ovarian cancer patients.

      Patients with ovarian cancer macroscopically limited to the ovary (early ovarian cancer) will
      receive injection of a tracer (patent blue or indocyanine green) which have already been
      proven safe and extremely effective in several other gynecologic and non-gynecologic
      malignancies. Then the retroperitoneal spaces will be opened as for a standard
      lymphadenectomy procedure and the lymph node marked with the tracer will be identified. After
      dissection of the sentinel node, lymphadenectomy will be completed according to current
      guidelines.

      Operative data, pathological findings and accuracy of sentinel node in predicting nodal
      status will be registered.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients with early ovarian cancer will receive sentinel node procedure before full lymphadenectomy, in order to assess the accuracy of sentinel node in diagnosing the presence of nodal metastases.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with procedure-related adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>The number of patients with procedure-related adverse events as assessed by CTCAE v4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection rate</measure>
    <time_frame>24 months</time_frame>
    <description>The rate of patients in whom the sentinel node is detected</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value</measure>
    <time_frame>24 months</time_frame>
    <description>The negative predictive value of sentinel node in assessing nodal status</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Sentinel Lymph Node</condition>
  <condition>Ovarian Cancer Stage I</condition>
  <arm_group>
    <arm_group_label>SENTINEL NODE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with ovarian cancer will receive sentinel node identification and they will be then submitted to complete pelvic and para-aortic lymphadenectomy (as per the present guidelines)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel node detection</intervention_name>
    <description>Patients will receive injection of tracer in the ovarian ligaments to identify the lymphatic drainage of the affected ovary and ultimately the sentinel node. Afterwards, systematic lymphadenectomy will be accomplished according to current guidelines.</description>
    <arm_group_label>SENTINEL NODE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Epithelial ovarian cancer

          -  Early stage disease limited to the ovary

        Exclusion Criteria:

          -  Evidence of extraovarian disease

          -  Allergy to the materials used
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>This is a gynecologic study therefore only biologically female patients will be included</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Scambia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giovanni Scambia Scambia, MD</last_name>
    <phone>+390630155629</phone>
    <email>giovanni.scambia@policlinicogemelli.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefano Uccella, MD</last_name>
    <phone>+393496093970</phone>
    <email>stefucc@libero.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nuovo Ospedale degli Infermi</name>
      <address>
        <city>Biella</city>
        <zip>13875</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianni Bonelli</last_name>
      <phone>+3901515151</phone>
      <email>gianni.bonelli@aslbi.it</email>
    </contact>
    <contact_backup>
      <last_name>Stefano Uccella</last_name>
      <phone>+393496093970</phone>
      <email>stefucc@libero.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fondazione di Ricerca e Cura 'Giovanni Paolo II'</name>
      <address>
        <city>Campobasso</city>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Cosentino</last_name>
      <phone>+393391194708</phone>
      <email>francesco.cosentino@policlinicogemelli.it</email>
    </contact>
    <contact_backup>
      <last_name>Luigi Turco</last_name>
      <phone>+390874312497</phone>
      <email>luigi.turco@policlinicogemelli.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena IRCCS</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Vizza, MD</last_name>
      <phone>06-52661</phone>
      <email>vizzaenrico@me.it</email>
    </contact>
    <contact_backup>
      <last_name>Giacomo Corrado, MD</last_name>
      <phone>06 52666657</phone>
      <email>giacomo.corrado@alice.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Scambia, MD</last_name>
      <phone>+390630155629</phone>
      <email>giovanni.scambia@policlinicogemelli.it</email>
    </contact>
    <contact_backup>
      <last_name>Stefano Uccella, MD</last_name>
      <phone>+393496093970</phone>
      <email>stefucc@libero.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Uccella S, Gisone B, Stevenazzi G, Ghezzi F. Laparoscopic sentinel node detection with ICG for early ovarian cancer: Description of a technique and literature review. Eur J Obstet Gynecol Reprod Biol. 2018 Feb;221:193-194. doi: 10.1016/j.ejogrb.2017.12.004. Epub 2017 Dec 6.</citation>
    <PMID>29224846</PMID>
  </results_reference>
  <results_reference>
    <citation>Sadeghi R. Feasibility of Sentinel Node Mapping in Ovarian Tumors: What Is the Evidence? Int J Gynecol Cancer. 2018 Feb;28(2):421-422. doi: 10.1097/IGC.0000000000001158.</citation>
    <PMID>29194194</PMID>
  </results_reference>
  <results_reference>
    <citation>Nyberg RH, Korkola P, Mäenpää JU. Sentinel Node and Ovarian Tumors: A Series of 20 Patients. Int J Gynecol Cancer. 2017 May;27(4):684-689. doi: 10.1097/IGC.0000000000000948.</citation>
    <PMID>28375928</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>March 10, 2019</last_update_submitted>
  <last_update_submitted_qc>March 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Prof. Giovanni Scambia</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>laparoscopy</keyword>
  <keyword>sentinel node</keyword>
  <keyword>lymphadenectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The IPD will be shared only with those making official request to the study investigator</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data will become available One year after publication, and they will be available for 6 months.</ipd_time_frame>
    <ipd_access_criteria>Direct request to the study PI</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

